Downloads
Abstract
Objectives: Evaluation of the result of first - line treatment and toxicity of Tyrosine kinase inhibitors in patients with advanced stage non - small cell lung cancer with EGFR mutations.
Methods: We conducted a prospective and retrospective descriptive study on 57 patients with stage IIIB/IIIC/IV non - small cell lung cancer, treated with 1st generation Tyrosine Kinase inhibitors at Hue Central Hospital and Hue University Hospital from 01/2020 - 06/2023.
Results: The complete response rate was 1.8%; the partial response rate was 45.6%; the stable disease rate was 21.1%; the progressive disease rate was 31.6%. The objective response rate was 47.4%; the disease control rate was 68.5%. Median progression - free survival was 9.0 ± 0.8 months, the shortest being 3 months, and the longest being 28 months. There was a statistically significant relationship between PFS and EGFR mutations (p < 0.05). Most patients have grade I, II toxicity and are mainly found on skin - mucosa and digestive system.
Conclusion: Tyrosine Kinase inhibitors in the treatment of advanced stage non - small cell lung cancer are effective, improving survival time for patients with a well - tolerated toxicity.
References
International Agency for Research on Cancer. Fact sheet: World, 2020. Available at https://gco.iarc.fr/today/data/factsheets/populations/900-world-fact-sheets.pdf. Accessed 9 August 2023.
International Agency for Research on Cancer. Fact sheet: Vietnam, 2020. Available at https://gco.iarc.fr/today/data/factsheets/populations/704-viet-nam-fact-sheets.pdf. Accessed 9 August 2023.
Ramalingam S, Belani C. Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions. Oncologist. 2008;13(1):5-13.
American Lung Association. Report: State of Lung Cancer, 2020. Available at https://www.lung.org/getmedia/381ca407-a4e9-4069-b24b-195811f29a00/solc-2020-report-final.pdf. Accessed 9 August 2023.
Herbst R.S, Heymach J.V, Lippma S.M. Lung Cancer. New England Journal of Medicine. 2008;359:1367-80.
Alanazi A, Yunusa I, Elenizi K, I Alzarea A. Efficacy and safety of tyrosine kinase inhibitors in advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutation: a network meta-analysis. Lung Cancer Manag. 2020;10(1):1758-1974.
Phạm Mai Thủy Tiên, Phạm Như Hiệp, Phan Cảnh Duy, Nguyễn Thanh Ái, Phan Thị Đỗ Quyên, Nguyễn Thị Diệu My. Đánh giá kết quả điều trị bước một ung thư phổi không tế bào nhỏ giai đoạn tiến xa, di căn có đột biến EGFR bằng thuốc ức chế tyrosine kinase (TKIs). Tạp chí Y học lâm sàng. 2018;(50):62-69.
Lê Thượng Vũ, Trần Văn Ngọc. Kết quả điều trị ung thư phổi không tế bào nhỏ giai đoạn tiến xa bằng Erlotinib (Tarceva) tại khoa Phổi Bv Chợ Rẫy. Y học TP.Hồ Chí Minh. 2013;17(1):105-10.
Jackman D, Pao W, Riely G.J, Engelman J.A, Kris M.G, Jänne P.A. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol. 2010;28(2):357-60.
Kim H.R, Shim H.S, Chung J.H, Lee Y.J, Hong Y.K, Rha S.Y et al. Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement. Cancer. 2012;118(3):729-39.
Takeda M, Okamoto I, Nakagawa K. Survival Outcome Assessed According to Tumor Response and Shrinkage Pattern in Patients with EGFR Mutation–Positive Non–Small-Cell Lung Cancer Treated with Gefitinib or Erlotinib. J Thorac Oncol. 2014; 9(2):200-204.
Nguyễn Thị Thái Hòa. Kết quả phân tích các dưới nhóm về đáp ứng điều trị và sống còn không tiến triển của ung thư phổi không tế bào nhỏ giai đoạn IV có đột biến EGFR điều trị Gefitinib. Journal of Community Medicine. 2020;4(57):5-7.
Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H et al. Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR. N Engl J Med. 2010;362:2380-88.
Pluzanski A, Krzakowski M, Kowalski D, Dziadziuszko R. Real-world clinical outcomes of first-generation and second-generation epidermal growth factor receptor tyrosine kinase inhibitors in a large cohort of European non-small-cell lung cancer patients. ESMO Open. 2020;5(6):e001011.
| Published | 26-12-2024 | |
| Fulltext |
|
|
| Language |
|
|
| Issue | No. 91 (2023) | |
| Section | Original article | |
| DOI | 10.38103/jcmhch.91.18 | |
| Keywords | Ung thư phổi không tế bào nhỏ, liệu pháp nhắm đích phân tử, giai đoạn tiến xa, RECIST 1.1, NCI CTCAE 5.0 Non - small cell lung cance, molecular targeted therapy, advanced stage, RECIST 1.1, NCI CTCAE 5.0 |
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2023 Journal of Clinical Medicine Hue Central Hospital